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Background. Pretravel health consultations help international travelersmanage travel-related illness risks through
education, vaccination, and medication. This study evaluated costs and beneﬁts of that portion of the health consul-
tation associated with malaria prevention provided to US travelers bound for West Africa.
Methods. The estimated change in disease risk and associated costs and beneﬁts resulting from traveler adher-
ence to malaria chemoprophylaxis were calculated from 2 perspectives: the healthcare payer’s and the traveler’s.
We used data from the Global TravEpiNet network of US travel clinics that collect de-identiﬁed pretravel data for
international travelers. Disease risk and chemoprophylaxis effectiveness were estimated from published medical
reports. Direct medical costs were obtained from the Nationwide Inpatient Sample and published literature.
Results. We analyzed 1029 records from January 2009 to January 2011. Assuming full adherence to chemo-
prophylaxis regimens, consultations saved healthcare payers a per-traveler average of $14 (9-day trip) to $372
(30-day trip). For travelers, consultations resulted in a range of net cost of $20 (9-day trip) to a net savings of $32
(30-day trip). Differences were mostly driven by risk of malaria in the destination country.
Conclusions. Our model suggests that healthcare payers save money for short- and longer-term trips, and that
travelers save money for longer trips when travelers adhere to malaria recommendations and prophylactic regi-
mens in West Africa. This is a potential incentive to healthcare payers to offer consistent pretravel preventive
care to travelers. This ﬁnancial beneﬁt complements the medical beneﬁt of reducing the risk of malaria.
Keywords. costs; beneﬁts; malaria prevention; pretravel health consultation.
The Centers for Disease Control and Prevention (CDC)
advises that international travelers seek pretravel health
consultations 4–6 weeks before departure [1]. These
consultations assess destination-speciﬁc risks (Figure 1)
and prepare travelers to reduce illness and injury through
education, vaccination, and medication. Effective con-
sultations tailor recommendations based on medical his-
tory and travel-related activities [1].
Most travelers do not visit healthcare providers for
pretravel health consultations despite CDC recommen-
dations [2–4], because of lack of knowledge or concern
about destination disease prevalence, insufﬁcient time,
or cost [2–4]. Furthermore, many commercial health
insurance plans do not cover travel-related vaccinations
and medications [5].
Malaria prevention is one important component of
consultations for travelers visiting malaria-endemic areas.
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Malaria is a mosquito-borne infectious disease, caused by proto-
zoa of the genusPlasmodium. In 2010,malariacaused216million
infections and approximately 650 000 deaths worldwide [1, 6].
For travelers toWest Africa, the risk of contractingmalaria, espe-
cially the potentially severe Plasmodium falciparum form, is rel-
atively high [1, 7].
To better understand the value of pretravel health consulta-
tions, we modeled costs and beneﬁts of malaria education and
chemoprophylaxis provided to US travelers destined for West




Microsoft Excel (Microsoft Corporation, Redmond, Washing-
ton) was used to calculate the model estimating the expected
value of the portion of pretravel health consultations targeted at
malaria risk reduction. Expected value was deﬁned as the diffe-
rence between the sum of clinic visit and chemoprophylaxis
costs and the monetary value of reduced risk of contracting
malaria. Final outcome measures were net costs or savings
using this equation:
Net costs or savings per traveler (expected value)
¼ Reduced risk of contracting malaria resulting from
pre-travel health consultation and chemoprophylaxis
adherence
Cost of malaria treatment  ½Cost of pre - travel
health consultation and chemoprophylaxis
Disease risk reduction resulted from a combination of chemo-
prophylaxis effectiveness and adherence.
We evaluated the model from 2 perspectives: payer’s (health
insurer) and traveler’s. The payer’s perspective was calculated
using direct costs of pretravel health consultations, chemopro-
phylaxis with adverse events treatment, and malaria treatment.
The traveler’s perspective included direct costs of copayments
for these categories and assumed the traveler was insured. Op-
portunity costs were included for lost work time to the traveler.
We did not quantify cost of death. All costs were expressed in
undiscounted 2009 dollars because costs and beneﬁts were in-
curred in the same year.
Pretravel Health Consultation Data: Travel Duration and Purpose
The Global TravEpiNet (GTEN) consortium clinic network
represents academic, private, pharmacy-based, and public health
medical practices [8].At the time of the analysis, GTEN included
18 US clinics and systematically collected pretravel health con-
sultation data. We identiﬁed 1029 of 13 235 GTEN travelers
bound for West Africa from January 2009 to January 2011
(SupplementaryAppendix, Section 1).WestAfrica includesBenin,
Burkina Faso, Cape Verde, Côte d’Ivoire, The Gambia, Ghana,
Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria,
São Tomé and Príncipe, Senegal, Sierra Leone, and Togo [1].
The top 3 self-reported travel purposes were business, leisure,
and visiting friends and relatives (VFR). Initial analyses deter-
mined that purpose-groups differed in trip duration and che-
moprophylaxis choice (Supplementary Appendix, Table A1,
Section 1). Median trip durations were 9 days (business), 14
days (leisure), 21 days (any travel purpose), and 30 days (VFR).
The median trip duration was used to model malaria risk differ-
ences assuming longer durations were associated with greater
risk. Group chemoprophylaxis choices were used to calculate
weighted averages of drug effectiveness, costs, and probability of
drug-related adverse events requiring medical attention. The ex-
pected value (net costs/savings per traveler) was estimated for
each subgroup of business, leisure, VFR, and all travelers regard-
less of purpose. For sensitivity analyses, costs were recalculated
using only 1 chemoprophylaxis at a time, and risk was varied to
reﬂect other behavioral factors affecting disease likelihood such
as staying in air-conditioned rooms, using insect repellent and
Figure 1. Examples of destination-speciﬁc diseases and health risks to
a traveler to West Africa assessed via a pretravel health consultation. The
pretravel health consultation will also provide an opportunity to conﬁrm
that routine vaccinations for diseases denoted in the shaded ovals are up-
to-date or to administer these vaccines. Abbreviations: HIV, human immu-
nodeﬁciency virus; STIs, sexually transmitted infections.
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bed nets, or chemoprophylaxis adherence, as well as destination
transmission intensity.
Epidemiologic and Clinical Assumptions
The published risk of travelers for contracting malaria in West
Africa was a point estimate of 24.2 cases per 1000 person-
months (Table 1) [9]. Daily risk was assumed to be spread
evenly over a month (ie, 0.81 cases per 1000 person-days in a
30-day month). The malaria-contraction risk was calculated by
median travel duration; for example, a leisure traveler’s malaria
risk during a 14-day trip was 11.3 per 1000. A 71% probability
of malaria hospitalization was used (Table 1).
A weighted average chemoprophylaxis was estimated by fre-
quency of prescription of:
• Atovaquone/proguanil: 250 mg atovaquone and 100 mg
proguanil hydrochloride, 1 tablet orally, daily, for 2 days before,
through 7 days after travel.
• Doxycycline: 100 mg orally, daily, for 2 days before,
through 4 weeks after travel.
• Meﬂoquine: 228 mg base (250 mg salt) orally, once a week,
for 2 weeks before, through 4 weeks after travel.
The weighted average chemoprophylaxis effectiveness for
each purpose and travel duration was estimated using published
values of 92.6%–95.8% (Table 1) [11–13]. The reduced model
probability of contracting malaria assumed 100% chemopro-
phylaxis regimen adherence using the following equation:
ðprobability of contracting malaria without chemoprophylaxisÞ
 ð1weighted average prophylactic effectivenessÞ
 ðadherence rateÞ
þ ðprobability of contracting malaria without
chemoprophylaxisÞ ð1 adherence rateÞ:
In the sensitivity analyses, chemoprophylaxis adherence was
reduced to 60%, making 40% of travelers unprotected.
Only those malaria chemoprophylaxis-related adverse events
requiring medical care were calculated with literature-based
adverse event probabilities (Table 1) [14].
Table 1. Input Variables and References
Item Baseline Valuea Rangea Reference





12–70 per 1000 person-mo [9, 10]
Probability of hospitalization for
malaria acquired in West Africab,c
71% 67%–74% [7], Unpublished 2009 USmalaria
surveillance data, CDC
Effectiveness of malaria chemoprophylaxis
Atovaquone/proguanil 95.8% 91.5%–97.5% [11]
Doxycycline 92.6% 79.9%–97.5% [12]
Mefloquine 94.5% 84.0%–98.1% [13]
Probability of chemoprophylaxis-related adverse events requiring medical attention
Atovaquone/proguanil 7% 2%–11% [14]
Doxycycline 6% 2%–10% [14]
Mefloquine 11% 6%–15% [14]
Percentage adherence with
chemoprophylaxis regimend
100% 60%; 100% [15], Assumption
Hourly compensation (US$, 2009) 32.79 15.98–48.66 [16, 17], Supplementary
Appendix
Lost workdays for malaria treatment
Ambulatory case 5 d 2–7 d Assumption
Hospitalized casee 10 d 6–24 d [18], Assumption
Abbreviation: CDC, Centers for Disease Control and Prevention.
a Baseline and range values were often taken from different resources. We used expert opinion to determine the most representative baseline values, and thus the
baseline values are different from the simple middle or median of the range.
b West Africa included Benin, Burkina Faso, Cape Verde, Côte d’Ivoire, The Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, São
Tomé and Príncipe, Senegal, Sierra Leone, and Togo [1].
c The probability was estimated by dividing the number of hospitalized malaria cases from West Africa by the number of all malaria cases from West Africa
(unpublished 2009 US malaria surveillance data, CDC).
d Reduced adherence rate here is the equivalent of not taking the drug as per recommendations to the point where no effective protection is obtained (eg, traveler
obtains prescription but takes no doses). Those who do take the drug are assumed to be fully adherent to the recommended dosages.
e The lost workdays for hospitalized cases included days spent at both hospital and home for recuperation. Because Plasmodium falciparum accounted for 87%
of hospitalized malaria cases where the disease was acquired in West Africa (unpublished 2009 US malaria surveillance data, CDC), length of stay at hospital of
P. falciparum from Nationwide Impatient Sample data [18] was used as the representative length of stay at hospital.
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Costs Associated With Pretravel Health Consultations
Healthcare Payer’s Perspective
Total payer pretravel clinic costs were calculated using allowable
billing charges associated with Current Procedural Terminology
(CPT) codes [19] of an average of $148 (range, $126–$170;
Table 2). The portion of a consultation associated with malaria
prevention was estimated at 14.8% of the total (Supplementary
Appendix, Section 2.2). Weighted malaria chemoprophylaxis
costs were included (weighting explained in the previous section)
[20]. Adverse event medical treatment costs were estimated as-
suming 1 physician ofﬁce visit and a prescription of prochlorper-
azine. Assumptions about physician-provided adverse event
treatment were based on expert opinions regarding the most
common complaint associated with chemoprophylaxis.
Traveler’s Perspective
Total traveler’s costs included out-of-pocket copayments for
the consultation, adverse event treatments, prescription drugs,
and opportunity costs of lost work time (Table 2). Lost work
time was set at 120 minutes for a travel clinic visit and 60
minutes for adverse event medical care and was valued at
$32.79 (Supplementary Appendix, Section 3). Traveler copay-
ments and lost work time were prorated by 14.8% related to
malaria prevention.
Costs Associated With Malaria Treatment
For both study perspectives, estimated treatment costs weighted
the probability that travelers would need ambulatory and/or
hospital medical care (Table 3).
Table 2. Costs (US$ 2009) Associated With Pretravel Health Consultations for Malaria Chemoprophylaxis: Healthcare Payer’s and
Traveler’s Perspectives
Item Baseline Valuea Rangea Reference
Healthcare payer’s perspective (direct medical costs)
Travel clinic visitb $148.52 $126.27–$170.77 [19]
Percentage of travel clinic visit
costs related to malaria prevention
14.8% . . . Supplementary Appendix
Malaria chemoprophylaxis (per adult dose)c
Atovaquone/proguanil $7.87 $6.40–$11.70d [20]
Doxycycline $1.08 $0.43–$1.78d [20]
Mefloquine $13.17 $9.46–$18.03d [20]
Physician visit to treat adverse eventse $80.50 $69.00–$92.00 [19]
Prescription drug for adverse eventsf $11.50 $7.00–$20.00 [20]
Traveler’s perspective
Direct costs
Copayment for travel clinic visit $30.00 $15.00–$170.77g [5], Assumption
Copayment for physician office visit
to treat adverse events
$20.00 $10.00–$50.00 [21], Assumption
Copayment for prescription drug $25.00 $10.00–$50.00 [21], Assumption
Indirect costs
Lost work hours for travel clinic visit
(120 min)h
$65.57 $31.96–$97.32 [16, 17], Supplementary Appendix
Lost work hours for physician visit
due to adverse events (60 min)h
$32.79 $15.98–$48.66 [16, 17], Supplementary Appendix
a Baseline and range values were often taken from different resources. We used expert opinion to determine the most representative baseline values, and thus the
baseline values are different from the simple middle or median of the range.
b The cost for a travel clinic visit was calculated by using Current Procedural Terminology (CPT) codes in common use by the Global TravEpiNet clinics and the range
of allowable billing charges associated with those CPT codes [19].
c The costs were calculated based on the following adult dose regimens: (1) atovaquone/proguanil, 250 mg atovaquone and 100 mg proguanil hydrochloride, 1
tablet orally, daily; (2) doxycycline, 100 mg orally, daily; and (3) mefloquine, 228 mg base (250 mg salt) orally, once a week [1].
d The lower and upper range values were 5th and 95th percentiles of listed wholesale prices, respectively.
e The cost of physician visit was estimated as the average of allowable billing charges of CPT code 99201 (office or other outpatient services, new patient level 1)
[19].
f The cost of prescription drug was estimated based on the protocol of prochlorperazine 10 mg, 3 times daily for 4 days, for vomiting and nausea [20].
g In case a traveler is uninsured or his/her health insurance does not cover travel-related preventions, it was assumed the traveler paid the upper limit of $170.77
out-of-pocket costs of a travel clinic visit.
h The costs for lost work hours were calculated with the estimated hourly compensation of $32.79 (Table 1).
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Table 3. Costs (US$2009) Associated With Malaria Treatment: Healthcare Payer’s and Traveler’s Perspectives
Item Baseline Valuea Rangea Reference
Healthcare payer’s perspective (direct medical cost)
Physician visit
Ambulatory caseb $431 $365–$497 [19]
Hospitalized casec $361.5 $306–$417 [19]
Test: blood filmd
Ambulatory case $52.50 $46–$59 [19]
Hospitalized case Included in hospitalization costs [18]
Drugs for treatmente
Ambulatory case $41.75 $32–$51.5 [20]
Hospitalized case Included in hospitalization costs [18]
Hospitalization costf $29 320 $8545–$33 906 [18]
Inpatient physician services 20% of hospital charge 10%–40% of
hospital charge
[22], Assumption
Travelers’ perspective (direct and indirect costs)
Direct costs
Copayment for physician visits
Ambulatory caseg $60 $30–$150 [5], Assumption
Hospitalized caseh $40 $20–$100 [5], Assumption
Copayment for prescription drug for treatment
Ambulatory case $25 $10–$50 [21], Assumption
Hospitalized case Included in hospitalization costs [18]
Hospitalization cost: copayment for
hospital room and board plus Inpatient
physician services charge
$250 plus 20% coinsurance of
inpatient physician services
charge





Lost work hours for physician visit for treatment
Ambulatory caseg,i $114.75 $55.93–$170.31 [16, 17], Supplementary Appendix
Hospitalized caseh,i $81.96 $39.95–$121.65 [16, 17], Supplementary Appendix
Lost workdays for medical carej
Ambulatory case $1311.44 $255.68–$2724.96 [16, 17], Supplementary Appendix
Hospitalized case $2622.88 $767.04–$9342.72 [16, 17], Supplementary Appendix
a Baseline and range values were often taken from different resources. Baseline and range values were often taken from different resources. We used expert
opinion to determine the most representative baseline values, and thus the baseline values are different from the simple middle or median of the range.
b The cost of physician visit for an ambulatory case was estimated using Current Procedural Terminology (CPT) codes for the total of 3 visits: the first visit for tests
(CPT 99205, office or other outpatient services, new patient level 5); the second visit for diagnosis and drug prescription (CPT 99212, office or other outpatient
services, established patient level 2); and the third visit for follow-up (CPT 99212, office or other outpatient services, established patient level 2). The range of
allowable billing charges associated with those CPT codes was used [19].
c The cost of physician visits for a hospitalized case was estimated based on the total of 2 visits: the first visit for referral to a hospital (CPT 99205, office or other
outpatient services, new patient level 5); and the second visit for follow-up after hospitalization (CPT 99212, office or other outpatient services, established patient
level 2) [19].
d The cost of blood film test for malaria was estimated based on CPT code 87207 [19].
e The average cost of prescription drugs for malaria treatment was estimated as the weighted average costs of recommended drugs by the Centers for Disease
Control and Prevention for uncomplicated malaria with Plasmodium malariae, Plasmodium ovale, or Plasmodium vivax [20, 23]. The weights were the proportion of
those cases from West Africa in 2009 US malaria surveillance data [7]. West Africa included Benin, Burkina Faso, Cape Verde, Côte d’Ivoire, The Gambia, Ghana,
Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, São Tomé and Príncipe, Senegal, Sierra Leone, and Togo [1].
f Because Plasmodium falciparum was 87% of hospitalized malaria cases where the disease was acquired in West Africa (unpublished 2009 US malaria
surveillance data, CDC), hospitalization costs of P. falciparum from Nationwide Inpatient Sample [16] data were used as the representative costs. The
hospitalization cost is “the amount the hospital charged for the entire hospital stay. It does not include professional (MD) fees.” [18] The lower and upper range
values were 5th and 95th percentiles of hospitalization costs, respectively [18].
g The cost of physician visits for an ambulatory case was estimated based on the total of 3 visits (initial admission, diagnosis based on lab tests, and follow-up). A
copayment for 1 physician visit was set at $20.
h The cost of physician visit for a hospitalized case was estimated based on the total of 2 visits (initial admission and follow-up). A copayment for 1 physician visit
was set at $20.
i The costs for lost work hours were calculated with the estimated hourly compensation of $32.79 (Table 1). The time that a patient would miss work was
estimated at 90 minutes for the initial physician visit and 60 minutes for each additional visit.
j Hours of lost workdays were estimated based on an 8-hour workday multiplied by the number of lost workdays (5 days for ambulatory care and 10 days for
hospital care) and estimated hourly compensation of $32.79 (Table 1).
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Healthcare Payer’s Perspective
The payer’s direct medical costs for hospitalized patients were 2
physician ofﬁce visits and hospitalization care. Ambulatory
patient medical costs were 3 physician visits, lab tests, and pre-
scription drugs. Direct medical costs were obtained from the
Nationwide Inpatient Sample (NIS) [18] and other publications
[19, 20, 22, 23]. Because 87% of West Africa–acquired malaria
cases requiring hospitalization were caused by P. falciparum
(unpublished 2009 US malaria surveillance data, CDC), NIS
hospitalization costs for P. falciparum were used.
Traveler’s Perspective
The traveler’s direct medical cost categories for ambulatory and
hospitalizations were the same as the payer’s and were modeled
as copayments (Table 3). Opportunity costs (ie, lost work
time), were estimated using (1) 10 days for hospital medical
care and 5 days for ambulatory care (8 hours a day); and (2)
multiple physician visits, 90 minutes for the initial visit and 60
minutes for additional visits. Lost workday estimates were a
sum of NIS [18] data and adjustments for recuperation.
Sensitivity Analyses
Multiway sensitivity analyses from both perspectives recalculat-
ed model results using upper and lower input ranges for each
purpose and duration of travel (Tables 1–3). For example, to es-
tablish a maximum upper estimate, net costs and savings were
calculated using only upper input values for the risk range
(instead of averages). This reﬂects a variety of unmeasurable be-
havioral factors that likely affect contracting malaria. These cal-
culations were done at both 100% and 60% chemoprophylaxis
adherence.
Furthermore, multiway sensitivity analyses included varying
the transmission intensity at the destination; we assumed the
risk-range of malaria contraction was the range of estimated inci-
dence rates of pediatric nonsevere malaria in West Africa [10].
The range reported (151–853 per 1000 person-years) was
assumed to be distributed evenly for each day (0.4–2.3 per 1000
person-days). We chose pediatric incident rates because travelers
would be immunologically naive with respect to malaria and
would have some similarity to young children in endemic areas.
We also calculated 1-way sensitivity analyses for both perspec-
tives using 1 chemoprophylaxis at a time instead of weighted
average costs and prescription rates of all malaria chemoprophy-
laxis options. Our ﬁnal calculation was the break-even risk point
where net cost/savings is equal to zero (Supplementary Appen-
dix, Section 8).
RESULTS
From the payer’s perspective, a weighted average cost to treat 1
malaria case was $25 250. The payers’ costs for pretravel health
consultations, malaria chemoprophylaxis, and adverse event
treatment ranged from $161 to $208. When travelers adhered
to chemoprophylaxis regimens, the likelihood of contracting
malaria was reduced by 95%–96%; this greatly reduced the like-
lihood that payers would pay $25 250 for malaria treatment
(Table 4). For example, the risk of contracting malaria was
reduced from 11.3 to 0.52 per 1000 for leisure travelers and
from 24.2 to 1.28 per 1000 for VFR travelers. This reduction
produced per-traveler net savings for payers between $14 and
$371, with respective ranges (lower bound and upper bound) of
−$212 to $614 and −$218 to $2324 (Table 5; Figure 2).
From the traveler’s perspective, weighted average out-of-pocket
malaria treatment costs were $3387 per case. Out-of-pocket
costs of pretravel health consultations and malaria chemopro-
phylaxis ranged from $44 to $46 (Table 5). With the 95%–96%
reduction in disease risk from chemoprophylaxis adherence,
the expected value (net cost or savings) ranged from a net cost
of approximately $20 (lower and upper bounds, −$101 to
$223) for a 9-day trip to a savings of $30 (lower and upper
bounds, −$99 to $788) for a 30-day trip (Table 5; Figure 2).
Multiway sensitivity analyses resulted in wide ranges of net
costs to savings; the range depended on travel duration and
chemoprophylaxis adherence (Figures 2 and 3). For travelers,
varying inputs at 100% adherence for short trips (9–14 days)
were likely to have a net cost; net savings were more likely for
longer trips. From the payer’s perspective, varying inputs at
100% adherence, even for short trips, resulted in more net
savings than costs. At 60% adherence, shorter trips usually re-
sulted in net costs from both perspectives. However, as travel
duration and malaria risk increased, net savings were more
likely from both perspectives.
For the payer’s-perspective, 1-way sensitivity analyses, assum-
ing 1 chemoprophylactic drug, only the less expensive doxycy-
cline increased net savings (Supplementary Appendix, Table A5).
In addition, for the “all travelers” group, the break-even risk point
at which net costs/savings is equal to zero was 8.6 per 1000. If
only doxycycline was prescribed, the break-even risk point fell to
3.5 per 1000, resulting in net savings for the wider range of risk
(Supplementary Appendix, Table A5). Therefore, assuming use
of doxycycline and 100% adherence, we found that net savings to
healthcare payers would result when the risk of malaria at a desti-
nation exceeds 0.13–0.33 per 1000 person-days of travel, indicat-
ing that even when risk approaches 0, chemoprophylaxis not
only reduces the risk of malaria, but results in cost savings. The
more expensive atovaquone/proguanil resulted in decreases in net
savings of 26%–60%.
DISCUSSION
Pretravel health consultations for malaria prevention, including
education for insect bite prevention and chemoprophylaxis
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prescriptions, more often than not resulted in net savings. Spe-
ciﬁcally, from the payer’s perspective, malaria prevention in
pretravel health consultations were, on average, cost savings
at the baseline and upper bound inputs, regardless of trip
duration. Pretravel health consultation payments and chemo-
prophylaxis (assuming 100% adherence) reduced per-traveler
risk-adjusted treatment costs. This result was consistent regard-
less of travel duration (9–30 days) for baseline inputs. For
upper bound inputs, savings increased sharply as risk in-
creased, whereas the lower bound resulted in decreasing net
costs as risk increased for each travel duration.
From the traveler’s perspective, net costs or savings changed
according to travel duration and malaria risk. Recalling that
purpose and travel duration were calculated together lends a
qualitative layer to the result interpretation. VFR travelers took
the longest duration of trips, and results show that those travel-
ing longer durations were more likely to save money with pre-
travel health consultations and chemoprophylaxis because their
risks of contracting malaria were higher. VFR travelers may
also be more likely to have increased risk of malaria because
they may stay in familial communities where malaria is
endemic, as opposed to shorter-duration business travelers who
may stay in larger cities and hotels. Regardless of duration,
purpose, or behavior patterns, travelers who engaged in higher-
risk behaviors (eg, no bednets, no insect repellent) would be
more likely to have a net savings from malaria pretravel care.
As with the payer’s perspective, the lower bounds of inputs into
the traveler’s perspective resulted in decreasing net costs as risk
increased for each trip duration.
The few published economic studies of pretravel health con-
sultations have focused on European travelers [24–26] where all
travelers are assumed to take only 1 type of chemoprophylaxis:
atovaquone/proguanil [26], meﬂoquine, or chloroquine and
proguanil [24]. These studies conclude that pretravel healthcare
and chemoprophylaxis are economically advantageous for trav-
elers to West Africa. By comparison, our study was based on
more detailed traveler characteristics and incorporated multi-
ple chemoprophylaxis types based on GTEN practices, a large
national consortium. These factors most likely improve the
real-world applicability of our results, especially as several anti-
malarial drugs remain in use for US travelers. Our study found
that payers, in most cases, saved money when travelers follow
pretravel health recommendations and chemoprophylaxis regi-
mens. Because malaria prevention saves money for third-party
payers, these results can help payers consider expanding reim-
bursements and more strongly emphasize the beneﬁts of pre-
travel health consultations and malaria chemoprophylaxis.
Many travelers do not understand their risk of contracting
malaria, whether in West Africa or elsewhere [27]. Where trav-
elers are insured, a payment of $44 could reduce their risk of
contracting malaria by at least 93%. This $44 expenditure to re-
ceive both a pretravel health consultation and chemoprophylaxis
Table 4. Risk of Contracting Malaria and Reduction in Risk Associated With Malaria Chemoprophylaxis to Travelers to West Africaa
Probabilities of Contracting
Malaria
Purpose of Travelb (Median Planned Length of Travel)c
Business (9 d) Leisure (14 d) All Purposes (21 d) VFRb (30 d)
Probability of contracting malaria
without chemoprophylaxisd
7.3 per 1000 11.3 per 1000 16.9 per 1000 24.2 per 1000
Probability of contracting malaria
with chemoprophylaxise
0.33 per 1000 0.52 per 1000 0.83 per 1000 1.28 per 1000
Reduction in probability of
contracting malaria (weighted
average efficacy of malaria
chemoprophylaxis)f
95.51% 95.41% 95.09% 94.70%
100% adherence for malaria chemoprophylaxis regimens was assumed.
Abbreviation: VFR, visiting friends and relatives.
a Costs were in 2009 dollars. West Africa included Benin, Burkina Faso, Cape Verde, Côte d’Ivoire, The Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali,
Mauritania, Niger, Nigeria, São Tomé and Príncipe, Senegal, Sierra Leone, and Togo [1]. Travelers to West Africa were identified as those travelers who planned to
visit 1 or more countries only in West Africa (Supplementary Appendix Section 1).
b For their pretravel health consultations, travelers were asked to report their purpose(s) of travel from the following (multiple choices were allowed): leisure,
business, returning to region of origin of self or family to visit friends and relatives, adoption, providing medical care, receiving medical care, research/education,
nonmedical service work, missionary work, military service, adventuring, attending large gathering or event, or other activities [8]. For this analysis, travelers who
reported only 1 of the 3 purposes (ie, business, leisure, and VFR) were selected. All purposes denote all travelers to West Africa.
c The median planned length of travel for each category of the purposes of travel was calculated among travelers to West Africa (Supplementary Table A1).
d Daily risk was assumed to be spread evenly over a month (ie, 0.81 cases per 1000 person-days in a 30-day month). The probability of contracting malaria without
chemoprophylaxis was calculated by median travel duration; eg, a leisure traveler’s malaria-risk during a 14-day trip was 0.81 per 1000 × 14 days = 11.3 per 1000.
e The probability of contracting malaria with chemoprophylaxis was calculated by multiplying the probability of contracting malaria without chemoprophylaxis by (1 –
weighted average efficacy of chemoprophylaxis), eg, (7.3/1000) × (1–0.9551) = 0.33/1000 for business travelers.
f The frequency of chemoprophylaxis prescription (Supplementary Table A1) was used as weights.
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may seem reasonable in contrast to the possibilities of serious
illness, and of personally needing to pay approximately $3400
for treatment. When the traveler is uninsured, potential direct
costs would be at least those of the payer (approximately $200
for consultation and chemoprophylaxis, and $25 250 for malaria
treatment). Because of this, uninsured travelers possibly would
bemore likely than insured travelers to receive a net savings from
pretravel care and chemoprophylaxis; however,wedidnot specif-
ically calculate the potential net savings for uninsured travelers
in this analysis. Knowledge of cost considerations may encourage
travelers to schedule a pretravel health consultation. Further-
more, our analyses of the impact of reduced adherence illustrated
the importance of following mosquito avoidance practices and
adhering to the prescribed malaria chemoprophylaxis regimens.
Our study focused solely on the singlemeasure of the econom-
ics of preventing malaria, but pretravel health consultations
encompass many aspects of travel medicine (Figure 1). During
consultations, practitioners provide comprehensive advice to
assist travelers with issues such as adverse conditions resulting
from extreme heat and cold, motor vehicle accidents or other ac-
tivities, or altitude sickness. Practitioners administer vaccines for
destination-speciﬁc infectious diseases and provide counseling
on infectious disease prevention. These consultations are also an
opportunity to conﬁrm that travelers are up-to-date on routine
vaccinations. Practitioners also provide advice on food and water
precautions and prescribe medications to treat travelers’ diar-
rhea. Evaluating costs and beneﬁts of all features encompassed in
pretravel health consultations could provide more comprehen-
sive estimates of overall costs and beneﬁts.
Our study had several limitations. First, the major limitation is
the uncertainty regarding the risk of malaria for travelers not
taking malaria chemoprophylaxis. We have based our primary
Table 5. Results of Baseline Analysis: Net Costs or Savings due to Pretravel Health Consultations Among Travelers to West Africaa
Stakeholder Cost Categories by Perspective
Purpose of Travelb and Median Planned Length of Travelc
Business 9 d Leisure 14 d All Purposes 21 d VFRb 30 d
Healthcare payer’s perspective
Weighted average direct cost for treatment,
US$d
25 250
Cost of pretravel health consultation,
chemoprophylaxis, and treatment of
adverse events associated with
chemoprophylaxis (Supplementary
Appendix Table A2), $
161.42 189.76 207.59 207.03
Net cost/savings per person per trip, $e 13.65 (net savings) 82.32 (net savings) 199.14 (net savings) 371.64 (net savings)
(Lower bound, upper bound) (−212.25, 613.72) (−240.08, 1003.94) (−246.79, 1571.12) (−218.43, 2324.12)
Traveler’s perspective
Weighted average out-of-pocket cost
(direct plus indirect) for treatment, $d
3387
Out-of-pocket cost of pretravel health
consultation, chemoprophylaxis, and
treatment of an adverse event associated
with chemoprophylaxis (Supplementary
Appendix Table A3), $
43.78 44.15 44.70 45.58
Net cost/saving per person per trip, $e −20.30 (net costs) −7.66 (net costs) 9.86 (net savings) 32.04 (net savings)
(Lower bound, upper bound) (−100.72, 223.21) (−100.16, 357.19) (−99.51, 545.19) (−99.11, 787.85)
100% adherence for malaria chemoprophylaxis regimens was assumed.
Abbreviation: VFR, visiting friends and relatives.
a Costs were in US 2009 dollars. West Africa included Benin, Burkina Faso, Cape Verde, Côte d’Ivoire, The Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali,
Mauritania, Niger, Nigeria, São Tomé and Príncipe, Senegal, Sierra Leone, and Togo [1]. Travelers to West Africa were identified as those travelers who planned to
visit 1 or more countries only in West Africa (Supplementary Appendix Section 1).
b For their pretravel health consultations, travelers were asked to report their purpose(s) of travel from the following (multiple choices were allowed): leisure,
business, returning to region of origin of self or family to visit friends and relatives, adoption, providing medical care, receiving medical care, research/education,
nonmedical service work, missionary work, military service, adventuring, attending large gathering or event, or other activities [8]. For this analysis, travelers who
reported only 1 of the 3 purposes (ie, business, leisure, and VFR) were selected. All purposes denote all travelers to West Africa.
c The median planned length of travel for each category of the purposes of travel was calculated among travelers to West Africa (Supplementary Table A1).
d Treatment cost of a malaria case was a weighted averaged between costs for ambulatory and hospital medical care using the probability of each care among
travelers to West Africa as the weight (Table 1).
e A negative value indicates that pretravel health consultation for malaria prevention will result in a net cost to healthcare payer or a traveler, whereas a positive value
indicates a net savings to a healthcare payer or a traveler. The lower and upper ranges were calculated by using lower and upper values of input and cost parameters
in Tables 1–3.
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analysis on the last risk assessment in the absence of chemopro-
phylaxis of which we are aware [9]. To mitigate this, we have also
included a sensitivity analysis assessing across a range of risk. A
reanalysis might be warranted if reliable and more up-to-date
malaria risk estimates of travelers who take no chemoprophylaxis
become available. A second limitation is that our models did not
include impact of individual traveler behavior, which could be
more inﬂuential than travel duration in determining the risk for
contracting malaria. To mitigate this limitation, we performed ad-
ditional sensitivity analyses taking varying risk levels into
account, although risk remains difﬁcult to quantify. Third, our
model does not incorporate costs for rarer but more serious po-
tential adverse events associated with chemoprohylactic regimens,
but instead assumes a relatively high rate of the most common
adverse events. Fourth, we did not quantify the potential travel
costs incurred from early departures from West Africa due to
illness, the pain and suffering associated with disease, or the cost
of death. As a result, our ﬁndings are most likely an underrepre-
sentation of the costs associated with malaria. Fifth, we assumed
that travelers were insured because the proportion of insured
versus uninsured travelers is unknown. Finally, our model also
focused solely on travel to West Africa, a region of particular risk
Figure 2. Net costs/savings for pretravel health consultations against malaria with 100% adherence to recommended malaria chemoprophylaxis regi-
mens: healthcare payer’s perspective (A); traveler’s perspective (B). The estimations were carried out by simultaneously varying the risk of contracting
malaria, input parameters, and various cost categories by using upper, baseline, and lower bounds of ranges (Tables 1–3). A negative value on the vertical
axis indicates that pretravel health consultations against malaria will result in a net cost to a healthcare payer or traveler, whereas a positive value indi-
cates a net savings to a healthcare payer or traveler. West Africa included Benin, Burkina Faso, Cape Verde, Côte d’Ivoire, The Gambia, Ghana, Guinea,
Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, São Tomé and Príncipe, Senegal, Sierra Leone, and Togo [1]. The arrow line (↔) on the horizontal
axis indicates the range of risk of contracting malaria adjusted for the length of travel using the estimated incidence rate (0.4 per 1000 person-days to 2.3
per 1000 person-days) [10]. The daily risk was assumed to be spread evenly over the median length of travel; eg, for a leisure traveler, the range of malaria
risk during a 14-day trip was from 5.6 per 1000 (0.4 per 1000 × 14 days) to 32.2 per 1000 (2.3 per 1000 × 14 days).
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for malaria. Future analyses could include economic evaluation
of travel to areas of the world with differing risks for malaria, al-
though our sensitivity analyses suggest parameters for costs and
savings for such trips. For instance, our model suggests that a pre-
travel consultation and malaria chemoprophylaxis (assuming, for
example, use of doxycycline and 100% adherence) would result
in net savings to healthcare payers when the risk of malaria at a
destination exceeds 0.13–0.33 per 1000 person-days of travel.
In conclusion, our study highlights that pretravel health con-
sultations with advice on insect bite prevention and malaria che-
moprophylaxis (assuming 100% adherence) cannot only reduce
the risk of contracting malaria for a traveler to West Africa, but
also likely save money to healthcare payers overall and to travel-
ers with high-risk situations, such as longer visit duration (2
weeks or more). Thus, there is a potential monetary incentive for
payers to offer pretravel preventive care to travelers.
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Figure 3. Multiway sensitivity analyses: 60% adherence to recommended malaria chemoprophylaxis regimens—net costs/savings for pretravel health
consultation against malaria: healthcare payer’s perspective (A); traveler’s perspective (B ). Multiway sensitivity analyses were conducted by simultaneously
varying the risk of contracting malaria, input parameters, and various cost categories by using upper, baseline, and lower bounds of ranges (Tables 1–3). A
negative value on the vertical axis indicates that pretravel medical consultation against malaria will result in a net cost to a healthcare payer or a traveler,
whereas a positive value indicates a net savings to healthcare payer or a traveler. West Africa included Benin, Burkina Faso, Cape Verde, Côte d’Ivoire, The
Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, São Tomé and Príncipe, Senegal, Sierra Leone, and Togo [1]. The arrow line
(↔) on the horizontal axis indicates the range of risk of contracting malaria adjusted for the length of travel using the estimated incidence rate (0.4 per 1000
person-days to 2.3 per 1000 person-days) [10]. The daily risk was assumed to be spread evenly over the median length of travel; eg, for a leisure traveler, the
range of malaria risk during a 14-day trip was from 5.6 per 1000 (0.4 per 1000 × 14 days) to 32.2 per 1000 (2.3 per 1000 × 14 days).
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